BHVN catalysts

    Catalysts and events linked to BHVN, newest first.

    BHVN stock catalysts and risks

    Latest published review: 2026-10-20

    DevelopmentTransmission channelEvidenceCondition to watch
    Biohaven partners with SK Biopharmaceuticals in $795M licensing deal
    2026-08-28 · Up
    non-dilutive milestone cash inflow from $795M licensing partnershipSource reports Biohaven licensing deal with SK Biopharmaceuticals worth up to $795 million for opakalim.Not recorded
    Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
    2026-08-28 · Up
    non-dilutive licensing capital and pipeline milestone monetizationBiohaven secured an exclusive licensing deal with SK Biopharmaceuticals worth up to $795M for its Kv7 platform.Not recorded
    Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim
    2026-08-28 · Up
    non-dilutive funding influx through $795M licensing agreementSigned up to $795 million global licensing agreement with SK Biopharmaceuticals.Not recorded

    Do these developments change your position?

    Review BHVN alongside your other holdings and identify which decision deserves attention first.

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    DateCardAvg 5d

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month